Pancreatic Cancer Research

ResearcherUniversity of MichiganNo recent work listed

Michael J. Levy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9958-3282; OpenAlex author ID A5104059885. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 2, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper, 1 trial · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers

Papers 20

  1. Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance. Co-author DOI 10.1016/j.gastha.2022.07.004↗
  2. Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound. Co-author DOI 10.1136/gutjnl-2021-324031↗
  3. Determining age and sex-specific distribution of pancreatic whole-gland CT attenuation using artificial intelligence aided image segmentation: Associations wit… Co-author DOI 10.1016/j.pan.2021.08.004↗
  4. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Co-author DOI 10.1016/j.cgh.2019.07.017↗
  5. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2019.11.003↗
  6. Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinom… First author DOI 10.1016/j.pan.2019.12.002↗
  7. Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospe… Co-author DOI 10.1016/j.pan.2020.07.410↗
  8. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Canc… Co-author DOI 10.1038/s41395-018-0403-2↗
  9. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2019.01.039↗
  10. Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. Co-author DOI 10.1117/1.jbo.24.11.118001↗
  11. Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1007/s11938-018-0195-x↗
  12. Risk of Pancreatic Cancer in Patients With Pancreatic Cysts and Family History of Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.01.049↗
  13. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Co-author DOI 10.1053/j.gastro.2018.04.025↗
  14. Endoscopic Ultrasound Fine-Needle Aspiration Diagnosis of Synchronous Primary Pancreatic Adenocarcinoma and Effects on Staging and Resectability. Last author DOI 10.1016/j.cgh.2016.08.009↗
  15. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1016/j.gie.2016.11.014↗
  16. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient st… Last author DOI 10.18632/oncotarget.9440↗
  17. Impact of celiac neurolysis on survival in patients with pancreatic cancer. Last author DOI 10.1016/j.gie.2014.12.036↗
  18. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  19. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2012-303108↗
  20. Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. Co-author DOI 10.1002/lsm.22073↗

Trials 1

  1. Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT01893294↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ferga C. Gleeson · 12 shared papers, 2015–2022 · strength 1.11
  2. Suresh T. Chari · 13 shared papers, 2015–2022 · strength 1.01
  3. Naoki Takahashi · 7 shared papers, 2017–2021 · strength 0.57
  4. Santhi Swaroop Vege · 7 shared papers, 2015–2022 · strength 0.55
  5. Shounak Majumder · 5 shared papers, 2019–2022 · strength 0.48
  6. Randall K. Pearson · 6 shared papers, 2015–2022 · strength 0.48
  7. Mark D. Topazian · 6 shared papers, 2015–2020 · strength 0.41
  8. Michael L. Kendrick · 5 shared papers, 2017–2022 · strength 0.41
  9. Ayush Sharma · 4 shared papers, 2018–2020 · strength 0.34
  10. Kenneth K. Wang · 5 shared papers, 2012–2020 · strength 0.32
  11. Lizhi Zhang · 3 shared papers, 2019–2022 · strength 0.32
  12. Vinay Chandrasekhara · 3 shared papers, 2020–2022 · strength 0.31
  13. Rondell Patrell Graham · 3 shared papers, 2016–2022 · strength 0.29
  14. Thomas C. Smyrk · 3 shared papers, 2018–2020 · strength 0.26
  15. Dhruv Pratap Singh · 2 shared papers, 2020–2021 · strength 0.20
  16. Mark Joseph Truty · 2 shared papers, 2017–2022 · strength 0.18
  17. Gloria M. Petersen · 3 shared papers, 2015–2020 · strength 0.17
  18. Sajan Jiv Singh Nagpal · 2 shared papers, 2019 · strength 0.15
  19. Steven R. Alberts · 2 shared papers, 2017–2020 · strength 0.15
  20. Ana García García de Paredes · 1 shared paper, 2022 · strength 0.14
  21. Nicholas Chia · 1 shared paper, 2022 · strength 0.14
  22. Jaime de la Fuente · 1 shared paper, 2022 · strength 0.12
  23. Sean Patrick Cleary · 1 shared paper, 2022 · strength 0.12
  24. Arjun Chatterjee · 1 shared paper, 2022 · strength 0.12
  25. Michael B. Farnell · 2 shared papers, 2017 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.